Invesco DB Oil Fund vs Novavax Inc — how do they compare? Invesco DB Oil Fund trades at $24.14 (market cap $255.13M), while Novavax Inc trades at $11.92 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 7.1× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is more actively traded (562,167 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Novavax Inc for 59 Days on average.
| DBO | NVAX | |
|---|---|---|
Market Cap | $255.13M | $1.82B |
Volume | 562,167 | 6,198,505 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $12.56 |
52-Week Low | $11.98 | $6.22 |
Typical Hold Time | 31 Days | 59 Days |
Enterprise Value | — | $1.39B |
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →